HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
-
ACADEMIA As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
-
REGULATORY Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
-
REGULATORY Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
-
REGULATORY Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
August 8, 2024
-
REGULATORY AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
August 8, 2024
-
BUSINESS NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
-
COMMENTARY Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
BUSINESS Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
August 6, 2024
-
BUSINESS Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
-
REGULATORY Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
-
REGULATORY Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
-
BUSINESS Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
-
REGULATORY Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
-
BUSINESS Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
-
BUSINESS Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
-
BUSINESS EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
-
BUSINESS Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
-
BUSINESS Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
-
ORGANIZATION Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
